We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$10B
AUM Growth
+$66.4M
Cap. Flow
+$419M
Cap. Flow %
4.17%
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$282M
2
CELC icon
Celcuity
CELC
+$271M
3
ERAS icon
Erasca
ERAS
+$189M
4
TNGX icon
Tango Therapeutics
TNGX
+$164M
5
IRTC icon
iRhythm Holdings
IRTC
+$70.2M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$269M
2
AXSM icon
Axsome Therapeutics
AXSM
+$162M
3
PODD icon
Insulet
PODD
+$92.3M
4
MASI
Masimo
MASI
+$88.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$85.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$11.7B
$1.04B 10.38%
1,993,687
– –
INSM icon
2
Insmed
INSM
$27B
$792M 7.88%
4,842,880
+1
+0% +$154
PTGX icon
3
Protagonist Therapeutics
PTGX
$10B
$533M 5.31%
5,059,053
– –
PTCT icon
4
PTC Therapeutics
PTCT
$5.98B
$528M 5.25%
7,746,415
– –
ARGX icon
5
argenx
ARGX
$53.3B
$518M 5.16%
709,446
+35,949
+5% +$28.1M
CGON icon
6
CG Oncology
CGON
$6.65B
$473M 4.7%
6,984,808
+4,972,681
+247% +$282M
CELC icon
7
Celcuity
CELC
$4.49B
$347M 3.45%
3,039,621
+2,489,461
+452% +$271M
TNGX icon
8
Tango Therapeutics
TNGX
$4.32B
$278M 2.77%
13,300,620
+11,809,392
+792% +$164M
ERAS icon
9
Erasca
ERAS
$6.43B
$261M 2.6%
16,157,175
+16,010,524
+10,917% +$189M
NTRA icon
10
Natera
NTRA
$44.7B
$250M 2.49%
1,250,000
-250,000
-17% -$53.8M
RDNT icon
11
RadNet
RDNT
$6.01B
$239M 2.38%
4,285,000
+346,500
+9% +$23.7M
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.04B
$235M 2.34%
3,346,025
+10,705
+0.3% +$748K
APGE icon
13
Apogee Therapeutics
APGE
$10.2B
$234M 2.33%
2,782,097
+70,000
+3% +$5.08M
SYRE icon
14
Spyre Therapeutics
SYRE
$9.14B
$210M 2.09%
4,171,996
– –
COGT icon
15
Cogent Biosciences
COGT
$6.58B
$210M 2.09%
5,458,675
-2,133,566
-28% -$78.8M
IRTC icon
16
iRhythm Holdings
IRTC
$4.17B
$197M 1.96%
1,668,500
+486,510
+41% +$70.2M
STOK icon
17
Stoke Therapeutics
STOK
$2.02B
$183M 1.82%
5,623,525
+76,669
+1% +$2.51M
CYTK icon
18
Cytokinetics
CYTK
$10.3B
$179M 1.78%
2,721,158
– –
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.87B
$159M 1.58%
7,144,524
– –
ESTA icon
20
Establishment Labs
ESTA
$2.37B
$151M 1.5%
2,655,695
+66,864
+3% +$4.57M
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
$148M 1.48%
3,685,045
-3,981,719
-52% -$85.8M
IMCR icon
22
Immunocore
IMCR
$1.74B
$147M 1.46%
4,869,798
– –
RGEN icon
23
Repligen
RGEN
$9.42B
$142M 1.41%
1,206,000
+142,000
+13% +$19.8M
NBIX icon
24
Neurocrine Biosciences
NBIX
$15.5B
$140M 1.39%
1,062,072
– –
GH icon
25
Guardant Health
GH
$21.1B
$137M 1.36%
1,481,033
– –
1
2 3 4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q1 2026 Portfolio in Review

As of Q1 2026, RTW Investments held 98 positions worth $10B, up 0.67% from $9.98B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments deployed $419M of net new capital in Q1 2026, opening 7 new positions and adding to 30 existing holdings. Its largest new stake was Waystar Holding Corp: 1,630,000 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apellis Pharmaceuticals, an estimated $85.8M trimmed.

  • RTW Investments's largest Q1 2026 buy was Waystar Holding Corp: 1,630,000 shares worth $39.3M.
  • RTW Investments added most to CG Oncology in Q1 2026, an estimated $282M increase.
  • RTW Investments's biggest Q1 2026 reduction was Apellis Pharmaceuticals, cutting an estimated $85.8M.
  • RTW Investments fully exited Penumbra in Q1 2026, selling an estimated $269M.
  • RTW Investments's ten largest holdings make up 50% of its $10B portfolio in Q1 2026.
  • RTW Investments opened 7 new positions and closed 10 in Q1 2026.
  • RTW Investments's portfolio value rose 0.67% quarter-over-quarter to $10B.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.